Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 239-243, February 2006

Ketamine displaces the novel NMDA receptor SPET probe [123I]CNS-1261 in humans in vivo☆

  • James M. Stone

      Affiliations

    • Institute of Psychiatry, King's College London, De Crespigny Park London, SE5 8AF UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 020 7848 0531.
    • ,
  • Kjell Erlandsson

      Affiliations

    • Institute of Nuclear Medicine, University College London, London, W1N 8AA UK
    • ,
  • Erik Årstad

      Affiliations

    • Institute of Psychiatry, King's College London, De Crespigny Park London, SE5 8AF UK
    • ,
  • Rodrigo A. Bressan

      Affiliations

    • Institute of Psychiatry, King's College London, De Crespigny Park London, SE5 8AF UK
    • ,
  • Lisa Squassante

      Affiliations

    • GlaxoSmithKline (GSK), Verona 37135, Italy
    • ,
  • Vincenza Teneggi

      Affiliations

    • GlaxoSmithKline (GSK), Verona 37135, Italy
    • ,
  • Peter J. Ell

      Affiliations

    • Institute of Nuclear Medicine, University College London, London, W1N 8AA UK
    • ,
  • Lyn S. Pilowsky

      Affiliations

    • Institute of Psychiatry, King's College London, De Crespigny Park London, SE5 8AF UK
    • Institute of Nuclear Medicine, University College London, London, W1N 8AA UK

Received 3 October 2005; received in revised form 2 December 2005; accepted 4 December 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ There are no conflicts of interest to report. LSP, EA, and KE were supported by a UK Medical Research Council Senior Clinical Research Fellowship to LSP. JS and RAB were supported by a research grant from GSK.

PII: S0969-8051(05)00294-5

doi:10.1016/j.nucmedbio.2005.12.001

Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 239-243, February 2006

Article Tools

* Image Usage & Resolution